Janeen Doyle serves as Chief Corporate and Business Development Officer at Janux Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel T cell engager therapies for solid tumor cancers. With over 20 years of experience in the biotech and pharmaceutical industries, Janeen has held senior leadership roles at companies including Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, where she spearheaded strategic partnerships, licensing deals, and M&A transactions totaling more than $5 billion in value. Her expertise spans corporate strategy, alliance management, and business development, honed through navigating complex regulatory landscapes and fostering collaborations that accelerate drug development pipelines. Throughout her career, Janeen has been instrumental in landmark achievements, such as leading the negotiation of a transformative $2.2 billion collaboration at Gilead for next-generation oncology assets and driving Amgen's expansion into immuno-oncology through key alliances with biotech innovators. Recognized as a "Top 25 Women Leaders in Biotech" by PharmaVoice, she has authored influential publications on strategic partnering in precision medicine and serves on the board of directors for several emerging life sciences ventures. Her track record of delivering high-impact deals has consistently positioned her organizations at the forefront of therapeutic innovation. At Janux Therapeutics, Janeen drives the company's corporate strategy and business development initiatives, forging partnerships that enhance its TRACTr® platform and advance clinical programs like JANX007 and JANX008 into late-stage development. Under her leadership, Janux has secured strategic investments and collaborations that bolster its mission to transform cancer treatment, positioning the company for sustained growth and breakthrough therapies.